ARCH Venture Partners XII, LLC
ARCH Venture Partners XII, LLC's purchase track record
How the stock did after each of ARCH Venture Partners XII, LLC's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/4/2026 | SPTX | $19.80M | +26.1% | pending | — |
| 10/27/2025 | NMRA | $5.00M | -24.2% | -17.5% | +4.3% |
| 8/1/2025 | PRME | $10.00M | +22.3% | -5.7% | +11.2% |
| 2/15/2024 | PRME | $20.00M | -9.7% | -43.7% | +10.2% |
| 11/13/2023 | NMRA | $412K | +51.0% | -25.1% | +18.4% |
| 11/3/2023 | NMRA | $2.64M | +29.6% | -21.9% | +17.6% |
| 9/22/2023 | NMRA | $2.87M | +58.7% | +19.8% | +21.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
NMRA noted among top stock movers today. NMRA appeared in today's list of top stock movements, reflecting notable price activity. The stock is currently trading near its support level of $1.60 and shows a low RSI, suggesting oversold conditions. Analyst consensus target remains at $6.14, well above the current price range.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Prime Medicine stock surges after FDA clears IND for PM647. Prime Medicine shares rose significantly after the U.S. FDA cleared the Investigational New Drug application for PM647, a gene editing therapy for alpha-1 antitrypsin deficiency. This regulatory approval allows the company to begin clinical trials for the treatment. The positive news for Prime Medicine occurred alongside a broader decline in gene-editing stocks triggered by recent developments involving Anthropic AI.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Guggenheim initiates coverage of Rapport Therapeutics, sets $65 target. Guggenheim began coverage of Rapport Therapeutics and assigned a price target of $65. The target sits above the company's 52‑week high of $52.93, indicating a positive outlook. The stock currently trades with a low RSI and near a strong support level, which may influence market reaction to the new estimate.
Transaction History
| SPTX | ▼ Sell | Other | 2,681,265 | — | 5/4/2026 | View on chart |
| SPTX | ▼ Sell | Other | 2,513,686 | — | 5/4/2026 | View on chart |
| SPTX | ▲ Buy | Open Market | 1,100,000 | $19.8M | 5/4/2026 | View on chart |
| NMRA | ▲ Buy | Open Market | 1,915,700 | $5.0M | 10/27/2025 | View on chart |
| PRME | ▲ Buy | Open Market | 3,030,300 | $10.0M | 8/1/2025 | View on chart |
| RAPP | ▼ Sell | Other | 3,728,738 | $0 | 6/10/2024 | View on chart |
| PRME | ▲ Buy | Open Market | 3,200,000 | $20.0M | 2/15/2024 | View on chart |
| NMRA | ▼ Sell | Other | 703,061 | — | 12/8/2023 | View on chart |
| NMRA | ▼ Sell | Other | 1,176,593 | — | 12/8/2023 | View on chart |
| NMRA | ▲ Buy | Open Market | 3,357 | $40K | 11/14/2023 | View on chart |
| NMRA | ▲ Buy | Open Market | 31,653 | $372K | 11/13/2023 | View on chart |
| NMRA | ▲ Buy | Open Market | 11,844 | $135K | 11/10/2023 | View on chart |
| NMRA | ▲ Buy | Open Market | 5,431 | $64K | 11/10/2023 | View on chart |
| NMRA | ▲ Buy | Open Market | 31,079 | $327K | 11/9/2023 | View on chart |
| NMRA | ▲ Buy | Open Market | 69,127 | $745K | 11/8/2023 | View on chart |
| NMRA | ▲ Buy | Open Market | 23,124 | $273K | 11/8/2023 | View on chart |
| NMRA | ▲ Buy | Open Market | 30,192 | $347K | 11/7/2023 | View on chart |
| NMRA | ▲ Buy | Open Market | 43,082 | $498K | 11/6/2023 | View on chart |
| NMRA | ▲ Buy | Open Market | 22,420 | $255K | 11/3/2023 | View on chart |
| NMRA | ▲ Buy | Open Market | 34,560 | $483K | 9/29/2023 | View on chart |
| NMRA | ▲ Buy | Open Market | 16,841 | $220K | 9/28/2023 | View on chart |
| NMRA | ▲ Buy | Open Market | 25,110 | $344K | 9/28/2023 | View on chart |
| NMRA | ▲ Buy | Open Market | 24,504 | $302K | 9/27/2023 | View on chart |
| NMRA | ▲ Buy | Open Market | 34,000 | $399K | 9/26/2023 | View on chart |
| NMRA | ▲ Buy | Open Market | 30,773 | $332K | 9/25/2023 | View on chart |
| NMRA | ▲ Buy | Open Market | 29,967 | $349K | 9/25/2023 | View on chart |
| NMRA | ▲ Buy | Open Market | 40,000 | $446K | 9/22/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Seaport Therapeutics Gains Analyst Attention Ahead of ECNP Data
Seaport Therapeutics has attracted new analyst coverage, with Canaccord Genuity and HC Wainwright both issuing price targets of $28 and $50 respectively. The company will present additional pharmacokinetic data from its Phase 1 GlyphAgo trial at the ECNP Congress in October. These developments add fresh information for investors to assess the drug’s progress. The stock remains near its 52‑week low, with a support level around $17.79.
Seaport Therapeutics Gains Analyst Attention Ahead of ECNP Data. Seaport Therapeutics has attracted new analyst coverage, with Canaccord Genuity and HC Wainwright both issuing price targets of $28 and $50 respectively. The company will present additional pharmacokinetic data from its Phase 1 GlyphAgo trial at the ECNP Congress in October. These developments add fresh information for investors to assess the drug’s progress. The stock remains near its 52‑week low, with a support level around $17.79.